Potential Cardiovascular Blockbuster Inclisiran Among New Filings At EMA
Executive Summary
The European Medicines Agency has agreed to review pan-EU marketing applications for a number of new medicines.
You may also be interested in...
Three Cell And Gene Therapies Reach Critical Review Stage In EU
A number of advanced therapies are likely to be approved in the EU this year.
Ide-Cel & Enhertu Sponsors Keep Fingers Crossed For EMA Fast-Track
Companies are due to learn this week whether the European Medicines Agency will fast-track its review of their soon-to-be-filed EU marketing applications.
Novartis In Line For Ofatumumab MS Approval In June
Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.